Rezolute, Inc.
NASDAQ:RZLTBiotechnology
+$0.30 today
- Market cap
- $411.10M
- Beta
- 0.65
- P/E (TTM)
- -6.5
- EPS (TTM)
- -$0.78
Volume 2.93M
Average 2.03M
RZLT Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Rezolute, Inc.NASDAQ: RZLT
Depreciation & Amortization · Q3 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q3 FY2026 depreciation & amortization of $8K rose 14.3% year over year, ahead of the +3.3% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 14.3% from the prior quarter. Over 3 fiscal years it compounded at +33.6% a year.
Context
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +14.3% holds above the trailing-twelve-month pace of +3.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 31K USD
- Year-over-year change
- -13.9%
- 4-year CAGR
- +24.3%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-06-30 | 31K | -13.9% |
| FY2024 | 2024-06-30 | 36K | +20.0% |
| FY2023 | 2023-06-30 | 30K | +130.8% |
| FY2022 | 2022-06-30 | 13K | +0.0% |
| FY2021 | 2021-06-30 | 13K | — |
Depreciation & Amortization vs competitors
How RZLT compares with its peers on the latest reported figures
- RZLT's LTM Mar 2026 depreciation & amortization of $31K is the lowest of the 5 companies compared; the peer median is $7.26M.
- Its year-over-year change of +3.3% is the highest of 5, against a peer median of -27.9%.
- Over three fiscal years its annual growth of +33.6% compares with a peer median of +8.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $34.01M | -4.7% | +24.3% | 5.1% | |
| LTM Mar 2026 | $11.75M | -9.8% | -6.6% | 3.2% | |
| LTM Mar 2026 | $2.77M | -57.2% | +62.5% | 2.3% | |
| LTM Mar 2026 | $67K | -46.0% | -18.0% | 7.8% | |
| LTM Mar 2026 | $31K | +3.3% | +33.6% | — | |
| Peer median (excluding RZLT) | $7.26M | -27.9% | +8.9% | 4.1% | |
Competitors are the stored peer set for RZLT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Jun 2021 | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 13K | 0 | 0 | 0 | 0 |
| Gross Profit | (13K) | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 14.99M | 32.49M | 43.81M | 55.74M | 61.53M |
| Selling, General & Admin | 7.91M | 9.36M | 12.18M | 14.68M | 18.37M |
| Operating Expenses | 22.88M | 41.84M | 55.99M | 70.42M | 79.89M |
| Depreciation & Amortization | 13K | 13K | 30K | 36K | 31K |
| EBITDA | (20.51M) | (39.24M) | (51.76M) | (68.42M) | (74.38M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (22.89M) | (41.84M) | (55.99M) | (70.42M) | (79.89M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 63K | 80K | 4.21M | 4.87M | 5.48M |
| Interest Expense | 375K | 1.81M | 0 | 0 | 0 |
| Other Income / Expenses | 1.99M | 783K | 4.2M | 1.96M | 5.48M |
| Income Before Tax | (20.9M) | (41.06M) | (51.79M) | (68.46M) | (74.41M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (20.9M) | (41.06M) | (51.79M) | (68.46M) | (74.41M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.72) | (2.26) | (1.01) | (1.33) | (0.98) |
| EPS (Diluted) | (2.72) | (2.32) | (1.01) | (1.33) | (0.98) |
| Weighted Avg Shares | 7.67M | 18.2M | 51.19M | 51.47M | 76M |
| Weighted Avg Shares (Diluted) | 7.67M | 19.49M | 51.19M | 51.47M | 76M |
Rezolute, Inc.
NASDAQ:RZLT
Intrinsic Alpha fair value
Locked
Current Price
$4.25
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.